Structure-activity study of L-amino acid-based N-type calcium channel blockers

被引:10
作者
Seko, T [1 ]
Kato, M [1 ]
Kohno, H [1 ]
Ono, S [1 ]
Hashimura, K [1 ]
Takimizu, H [1 ]
Nakai, K [1 ]
Maegawa, H [1 ]
Katsube, N [1 ]
Toda, M [1 ]
机构
[1] Ono Pharmaceut Co Ltd, Minase Res Inst, Mishima, Shizuoka 6188585, Japan
关键词
D O I
10.1016/S0968-0896(02)00558-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthesis and structure-activity relationship (SAR) study Of L-amino acid-based N-type calcium channel blockers are described. The compounds synthesized were evaluated for inhibitory activity against both N-type and L-type calcium channels focusing on selectivity to reduce cardiovascular side effects due to blocking of L-type calcium channels. In the course of screening of our compound library, N-(t-butoxycarbonyl)-L-aspartic acid derivative la was identified as an initial lead compound for a new series of N-type calcium channel blockers, which inhibited calcium influx into IMR-32 human neuroblastoma cells with an IC50 Of 3.4muM. Compound la also exhibited blockade of N-type calcium channel current in electrophysiological experiment using IMR-32 cells (34% inhibition at 10 muM, n = 3). As a consequence of conversion of amino acid residue of I a, compound 12a, that include N-(t-butoxycarbonyl)-L-cysteine, was found to be a potent N-type calcium channel blocker with an IC50 of 0.61 muM. Thus, L-cysteine was selected as a potential structural motif for further modification. Optimization of C- and N-terminals Of L-cysteine using S-cyclohexylmethyl-L-cysteine as a central scaffold led to potent and selective N-type calcium channel blocker 21f, which showed improved inhibitory potency (IC50 0.12 muM) and 12-fold selectivity for N-type calcium channels over L-type channels. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1901 / 1913
页数:13
相关论文
共 18 条
[1]   CLASSES OF CALCIUM CHANNELS IN VERTEBRATE CELLS [J].
BEAN, BP .
ANNUAL REVIEW OF PHYSIOLOGY, 1989, 51 :367-384
[2]  
CLEMENTI F, 1986, J NEUROCHEM, V47, P291
[3]   FLUNARIZINE BLOCKS ELEVATION OF FREE CYTOSOLIC CALCIUM IN SYNAPTOSOMES FOLLOWING SUSTAINED DEPOLARIZATION [J].
COHAN, SL ;
REDMOND, DJ ;
CHEN, M ;
WILSON, D ;
CYR, P .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1993, 13 (06) :947-954
[4]   N-type calcium channel blockers in pain and stroke [J].
Cox, B ;
Denyer, JC .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (10) :1237-1250
[5]  
COX B, 2000, CURRENT REV PAIN, V4, P188
[6]   Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties [J].
Hu, LY ;
Ryder, TR ;
Rafferty, MF ;
Feng, MR ;
Lotarski, SM ;
Rock, DM ;
Sinz, M ;
Stoehr, SJ ;
Taylor, CP ;
Weber, ML ;
Bowersox, SS ;
Miljanich, GP ;
Millerman, E ;
Wang, YX ;
Szoke, BG .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (20) :4239-4249
[7]   The discovery of [1-(4-dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethylbutyl)-phenyl]-(3-methyl-but-2-enyl)-amine, an N-type Ca+2 channel blocker with oral activity for analgesia [J].
Hu, LY ;
Ryder, TR ;
Rafferty, MF ;
Taylor, CP ;
Feng, MR ;
Kuo, BS ;
Lotarski, SM ;
Miljanich, GP ;
Millerman, E ;
Siebers, KM ;
Szoke, BG .
BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (06) :1203-1212
[8]   An evaluation of intrathecal ziconotide for the treatment of chronic pain [J].
Jain, KK .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (10) :2403-2410
[9]   Ca2+ channel antagonists and neuroprotection from cerebral ischemia [J].
Kobayashi, T ;
Mori, Y .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 363 (01) :1-15
[10]   Therapeutical application of voltage-gated calcium channel modulators [J].
Kochegarov, AA .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (02) :243-287